KALY Announces Growing CBD Candy Sales In Market Anticipated To Reach $22 Billion
Kali has recently launched a line of CBD infused candies under the brand name Hemp4mula.
Read More
Category: Biomedical
AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company
The purchase order is a refill of an initial order announced in February 2019 for 7,500 boxes containing 225,000 pieces of AXIM’s cannabinoid-based controlled-release gum.
Read More
CV Sciences’ PlusCBD Oil™ Used in First Study Examining Clinical Benefit of CBD for Patients with PTSD
The study examined the effect of oral CBD administration on symptoms of PTSD in a series of 11 adult patients at an outpatient psychiatry clinic.
Read More
AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
AXIM® Biotech plans to formulate a chewing gum under this invention that contains feverfew extract, cannabidiol (CBD) and/or cannabigerol (CBG) for treatment of symptoms that often accompany migraines.
Read More
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009).
Read MoreGET LISTED
